The uptake of 177Lu-FAPI-Ibu3 in tumors was 2.5-fold greater than that of 177Lu-FAPI-04 in A549-FAP tumor-bearing mice, and the ratios of absorbed dose in tumor-to-liver and tumor-to-kidney were significantly elevated. This evidence concerns the gene FAP and neoplasm.